CKLSF (CK Life Sciences International Holdings) 3-Year ROIIC % : -348.98% (As of Dec. 2025)


CKLSF CK Life Sciences International Holdings Inc CKLSF
39 GF Score
Price $0.09
GF Value $0.11
! 5 Warning Signs
View Full Analysis

What is CK Life Sciences International Holdings 3-Year ROIIC %?

CK Life Sciences International Holdings CKLSF +28.57% 39 3-Year ROIIC % is -348.98 as of Dec. 2025. GuruFocus rates CKLSF with a GF Score™ of 39/100 and a GF Value™ of $0.11. The stock has 5 warning signs investors should review. Among 1,325 Biotechnology companies, CK Life Sciences International Holdings ranks worse than 85.81% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. CK Life Sciences International Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -348.98%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for CK Life Sciences International Holdings's 3-Year ROIIC % or its related term are showing as below:

CKLSF's 3-Year ROIIC % is ranked worse than
85.81% of 1325 companies
in the Biotechnology industry
Industry Median: -4.44 vs CKLSF: -348.98

CK Life Sciences International Holdings  (OTCPK:CKLSF) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


CK Life Sciences International Holdings 3-Year ROIIC % Related Terms


CK Life Sciences International Holdings 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for CK Life Sciences International Holdings's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings 3-Year ROIIC % Chart

CK Life Sciences International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.15 -10.97 6.91 12.77 -348.98

CK Life Sciences International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.91 0.00 12.77 0.00 -348.98

CKLSF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison

For the Biotechnology subindustry, CK Life Sciences International Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CK Life Sciences International Holdings 3-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where CK Life Sciences International Holdings's 3-Year ROIIC % falls into.


CKLSF
39GF Score
CK Life Sciences International Holdings Inc CKLSF
3-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CK Life Sciences International Holdings 3-Year ROIIC % Calculation

CK Life Sciences International Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -16.84 (Dec. 2025) - 20.0282895 (Dec. 2022) )/( 1506.432 (Dec. 2025) - 1494.98 (Dec. 2022) )
=-36.8682895/11.452
=-321.94%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of -348.98 mean?
CK Life Sciences International Holdings (CKLSF) has a 3-Year ROIIC % of -348.98 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #1137 out of 1325 companies in the Biotechnology industry, placing it in the top 85.8%.
Is CK Life Sciences International Holdings' 3-Year ROIIC % too high?
CK Life Sciences International Holdings' current 3-Year ROIIC % is -348.98. Based on the distribution chart, CK Life Sciences International Holdings ranks #1137 out of 1325 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #1137 out of 1325 companies for 3-Year ROIIC %. This places CK Life Sciences International Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current 3-Year ROIIC % is -348.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current 3-Year ROIIC % of -348.98. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current 3-Year ROIIC % is -348.98. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current 3-Year ROIIC % is -348.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?

Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued. The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.

Key valuation signals for CKLSF:

  • 3-Year ROIIC %: -348.98
  • GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CK Life Sciences International Holdings Business Description

Other Exchanges 00775:Hong Kong
Address 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score

Get the complete analysis for CKLSF

3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price
$0.11
GF Value